
LEAH Labs
LEAH Labs is a YC Winter 2019 (W19) company. Based in Minneapolis, MN, USA. Team of 4.
About LEAH Labs
Summary
LEAH Labs develops CAR-T cell therapies for dogs with cancer, starting with B cell lymphoma, the canine equivalent of human non-Hodgkin's lymphoma. The company's virus-free gene editing platform, GeneWeld, cuts the cost of engineering a CAR-T dose to roughly $500, replacing palliative care as the standard option for pet owners and general practice veterinarians. Data and biological insights from canine trials directly inform the next generation of human CAR-T therapies.
Business model
Regulated under the USDA rather than the FDA, enabling a cost-effective full-stack commercial path from hypothesis to clinical validation.
Go-to-market
General practice veterinarians across the U.S. are the target customer, replacing current referral pathways to specialty oncologists; pet owners enroll through fully funded clinical trials at active trial sites.
From the Y Combinator listing
Living therapies for pets first, and their people next
LEAH Labs is building living therapies for pets first, and their people next. We're first focused on CAR-T cell therapy for dogs with B cell lymphoma, the naturally occurring clinical analog of human non-Hodgkin's lymphoma. CAR-T cells are curative in humans, and our early results are showing the same - we're inducing remissions in pets with late stage lymphomas. Our virus-free gene editing platform allows us to engineer a dose of CAR-T cell therapy for ~$500, and brings the promise of a curative outcome. Given our safety and efficacy data to date, we believe this product could be used by general practice veterinarians, meaning we have thousands of customers all across the USA who typically treat with palliative care or refer cancer patients to specialty oncologists. Our CAR-T cell platform is regulated by the USDA, not the FDA, affording us a cost effective "full stack" to iterate and innovate on CAR-T cell therapy from a hypothesis through clinical validation.
Facts
- Healthcare / Healthcare -> Therapeutics
- Minneapolis, MN, USA
- 4
- Active
- Early
Founders (1)
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works